Autologous Lymphoid Effector Cells Specific Against Tumor Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of cytotoxic, autologous lymphoid effector cells specifically targeted towards tumor cells, with potential immunomodulating and antineoplastic activities. The autologous lymphoid effector cells are prepared by drawing a blood sample containing the required precursors for CD4+ helper T-cells, CD8+ cytotoxic T-cells, and natural killer (NK) cells from a cancer patient. The precursor cells are activated, selected and expanded to generate mature autologous lymphoid effector cells with the potential for enhanced tumor recognition. Upon readministration into the patient, the autologous lymphoid effector cells may induce both humoral and cellular immune responses against tumor cells. This may result in the immune-mediated inhibition of tumor cell proliferation, which leads to tumor cell death.

**Synonyms:** - ALECSAT - AUTOLOGOUS EX VIVO EXPANDED CD4+-ENRICHED LEUKOCYTES TREATED WITH THE DE-METHYLATING AGENT 5-AZA-DEOXYCYTIDINE - Autologous Activated Cytotoxic T Lymphocytes/Natural Killer Cells